Co-Inventors
Schnell, Matthias
Frieman, Matthew
Hensley, Lisa
Wirblich, Christoph
Blaney, Joseph
Coleman, Christopher
Therapeutic Areas
Respiratory
Rare/Neglected Diseases
Pulmonology
Infectious Disease
Immunology
The technology in focus is a cutting-edge bivalent vaccine that simultaneously offers protection against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the rabies virus. In pre-clinical trials utilizing mouse models, the vaccine has demonstrated significant immunogenicity, prompting a strong immune response, and has effectively reduced the viral yield of MERS-CoV. Its dual-protective nature sets a new precedent for vaccine development, particularly in the context of zoonotic diseases where the potential for interspecies transmission poses a global health risk. Designed for use in both humans and animals, this vaccine candidate is poised to be a vital tool in areas with high exposure risk to these viruses, offering a strategic defense for communities and service personnel in affected regions and enhancing overall epidemic preparedness.
Commercial Applications
This innovative bivalent vaccine has the potential to transform public health strategies through its application in several key areas. It can be utilized in general healthcare settings for routine immunization programs, significantly impacting global health by reducing the incidence of both MERS-CoV and rabies. In the veterinary sector, it can protect wildlife and domestic animals, thereby curbing the zoonotic transmission of these viruses to humans. The vaccine is particularly beneficial for high-risk groups such as laboratory personnel, veterinarians, animal handlers, travelers to endemic areas, and military or diplomatic staff stationed overseas. Moreover, its deployment in epidemic response initiatives can enhance emergency preparedness against potential MERS-CoV outbreaks, providing a robust tool for international health organizations and governments in managing public health crises.
Competitive Advantages
The bivalent vaccine's primary competitive advantage lies in its dual-action formula, capable of inducing immunity against both MERS-CoV and rabies with a single inoculation. This not only streamlines vaccination protocols but also reduces healthcare costs and logistical complexity. Additionally, it addresses a critical need for vaccines that can protect against multiple pathogens, particularly in regions where both viruses are a concern. The vaccine’s efficacy in animal models suggests a high potential for success in human applications, promising to fill a gap in current vaccine offerings and providing a unique solution in the fight against these infectious diseases.
